Business Wire

Horizon3.ai Raises $100M to Cement Leadership in Autonomous Security

10.6.2025 13:30:00 EEST | Business Wire | Press release

Share

Horizon3.ai, the company behind the NodeZero® Autonomous Security Platform, today announced a $100 million Series D funding round led by NEA, with participation from SignalFire, Craft Ventures and 9Yards Capital. As part of the investment, Lila Tretikov, Partner and Head of AI Strategy at NEA and former Deputy CTO of Microsoft, will join the Horizon3.ai Board of Directors.

“Over the past four years, we’ve proven that using AI to hack companies isn’t science fiction—it’s real, and it’s delivering measurable results at scale. There are now over 3,000 organizations using NodeZero globally to conduct penetration tests. We’re sustaining 100%+ year-over-year ARR growth, and we are now Rule of 40-positive, which means we’re not just growing—we’re growing efficiently,” said Snehal Antani, CEO and Co-founder of Horizon3.ai. “This raise marks the next chapter in our mission to lead the Autonomous Security category.”

“Security teams are tired of chasing CVEs, false positives, and compliance checkboxes. They want to find and fix what actually matters, verify it’s resolved, and go home early,” said Antani. “The hardest part of the job as a CIO is deciding what not to fix. The second hardest part is proving to the board that your security initiatives are meaningfully reducing risk. NodeZero plays a critical role in reducing your threat exposure over time.”

Targeting an $80B Total Addressable Market: Autonomous Security

The cybersecurity market is undergoing a generational shift. NodeZero successfully compromised a bank in 4 minutes with no humans required, far faster than the reaction time of the bank’s security team and their best-in-class tools. Similarly, adversaries are leveraging AI to exponentially increase the sophistication, complexity, speed and scale of attacks. The Horizon3.ai thesis is simple: the future of cyber will be algorithms fighting algorithms—at machine speed—with humans by exception. This requires a fundamental rebuild of every part of the cybersecurity stack. And to do so effectively, you need a deep understanding of how attackers operate—and an AI system that can use offensive insights to drive defensive improvements. Horizon3.ai is leading this shift.

Horizon3.ai has already realized what others are just beginning to imagine. NodeZero is a fully autonomous security system operating in live production environments—executing real attacks, uncovering real risk, and delivering real results,” said Antani.

Powered by reinforcement learning, graph reasoning, and AI, NodeZero doesn't simulate adversaries—it thinks and acts like one. Each cyber attack against production systems executed by NodeZero collects training data used to improve its algorithms, creating a compounding data advantage that no other platform can match. This is the foundation for the next era of cybersecurity, where AI doesn’t just find risk, but continuously improves defenses. Horizon3.ai isn’t chasing the future—it’s building it.

Use of Proceeds: Accelerating Toward the Future

With this funding, Horizon3 is accelerating across three strategic fronts:

  • Scale through partners – Doubling down on its partner ecosystem to meet growing demand across the Americas, EMEA, and APAC.
  • Product innovation – Expanding into web application pentesting, vulnerability management, and precision defense, where NodeZero can remediate findings and tune defensive tools.
  • Winning the federal market – Scaling its success with the Defense Industrial Base through the NSA’s Continuous Autonomous Pentesting (CAPT) program, accelerating FedRAMP High usage, and expanding into Secret and Top Secret workloads to help secure the nation’s most mission-critical systems.

“What drew us to Horizon3.ai is the clarity of their mission and the speed at which they’re executing it,” saidAaron Jacobson, Partner at NEA. “They are defining a new security category—autonomous security—and are already the go-to solution for red and blue teams alike. We’re thrilled to lead this round and support the company’s next phase of growth.”

“Snehal and the Horizon3.ai team are tackling one of the biggest problems in cybersecurity: automating both sides to ensure maximum defensibility against automated and AI-driven attacks,” said Lila Tretikov, Partner and Head of AI Strategy at NEA. “Their customers love NodeZero, and the team has proven to operate with excellence at scale, which is why Horizon3.ai is transforming how security is done. I’m excited to join the board and help shape this next chapter.”

The impact is immediate and measurable. In one recent pentest, NodeZero gained access to sensitive US aircraft carrier design data through a third-party supplier. No humans were involved in the pentest. The platform autonomously compromised the network, gained access to sensitive data, and then guided defenders on exactly what to fix to prevent a breach.

“My old boss used to say, ‘don’t tell me we’re secure, show me, then show me again tomorrow, and again next week, because our environment is always changing and the enemy always has a vote,’” said Antani.

To learn more about NodeZero visit www.horizon3.ai.

For media inquiries and interviews, please see the Media Contact below.

About Horizon3.ai

Horizon3.ai is the leader in autonomous security. Our platform, NodeZero, continuously finds and exploits real-world attack paths so defenders can fix what matters and prove they’re secure. Founded by former U.S. Special Operations cyber operators and enterprise security leaders, Horizon3.ai is trusted by over 3,000 organizations worldwide—from Fortune 500 companies to national defense partners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250610254822/en/

Contacts

Media Contact:
Ed Kraft
SourceCode Communications
horizon3@sourcecodecomms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye